Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.
January 09, 2025 08:00 ET
|
Esperion Therapeutics, Inc.
– Leading Physician Expert to Discuss Continued Unmet Need in LDL-Cholesterol Management to Prevent Cardiovascular Disease – ANN ARBOR, Mich., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:...
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
January 02, 2025 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 43rd Annual J.P. Morgan Healthcare Conference on...
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
December 18, 2024 07:00 ET
|
Esperion Therapeutics, Inc.
– $150 Million Senior Secured Term Loan Credit Facility and New $100 Million Convertible Note to Repay Significant Portion of Existing $265 Million Convertible Debt – – New Facility Represents $150...
Esperion Announces $210 Million Convertible Debt Financing
December 13, 2024 06:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (the “Company”) (NASDAQ: ESPR) today announced that it entered into privately negotiated exchange and subscription agreements (the...
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
December 12, 2024 08:00 ET
|
Esperion Therapeutics, Inc.
– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with Tiered Royalties on Product Sales – – Israel-Based Commercial Organization Brings Successful Track Record Commercializing...
Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk
December 02, 2024 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has filed New Drug Submissions (NDSs) to Health Canada for NEXLETOL and NEXLIZET, once-daily,...
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
November 26, 2024 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka) has submitted a New Drug Application (NDA) to the Japanese...
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
November 21, 2024 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Piper Sandler 36th Annual Healthcare...
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
November 18, 2024 10:30 ET
|
Esperion Therapeutics, Inc.
– An Exploratory Analysis Reports Patients with PAD Who Took Bempedoic Acid Were 36% Less Likely to Experience a Major Adverse Limb Event Compared to Placebo – ANN ARBOR, Mich., Nov. 18,...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 08, 2024 16:15 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 7, 2024, the Company granted four new employees 12,900 restricted stock units (RSUs)...